Filing Details
- Accession Number:
- 0001213900-25-015019
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-02-18 21:54:19
- Reporting Period:
- 2025-02-18
- Filing Date:
- 2025-02-18
- Accepted Time:
- 2025-02-18 21:54:19
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
2028614 | Drugs Made In America Acquisition Corp. | DMAA | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1927032 | Lynn Stockwell | C/O Drugs Made In America Acq. Corp. 1 East Broward Boulevard, Suite 700 Fort Lauderdale FL 33301 | Ceo And Exe. Chair Of Board | Yes | Yes | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Ordinary Shares | Acquisiton | 2025-02-18 | 30,000 | $0.00 | 4,188,780 | No | 4 | P | Indirect | See Footnotes |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | See Footnotes |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Ordinary Shares | Rights to receive ordinary shares | Acquisiton | 2025-02-18 | 30,000 | $0.00 | 30,000 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
430,000 | No | 4 | P | Indirect |
Footnotes
- Reflects the 30,000 private units acquired by Drugs Made In America Acquisition LLC, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $300,000. Lynn Stockwell is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Ms. Stockwell disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of her pecuniary interest therein.
- The rights convert automatically into ordinary shares at the completion of the Issuer's initial business combination.